EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

Meet the Author

Jamie Pagliaro

PRESIDENT & CEO

Leading the company’s mission to transform autism diagnosis and care through innovation. Driving the commercialization of FDA-authorized technology that leverages the first validated biomarker for autism (eye gaze) to enable earlier, more accurate diagnosis and ongoing outcome measurement. Oversee corporate strategy, go-to-market execution, product development, and strategic partnerships to expand access, adoption, and impact for individuals with autism and their families worldwide.

Written By Jamie Pagliaro

Latest Articles

View All Posts

From Fixing to Flourishing: A Brief History of Autism in America & Beyond

Rethinking The Autism Diagnosis Process

Request A Demo

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder